Novel Methods and Tracers for Breast Cancer Imaging
Section snippets
Breast Cancer
Breast cancer is the most common malignancy in women, accounting for approximately 29% of all cancers in females. It is estimated that in the year 2012, there will be nearly 226,870 new cases of breast cancer and cause approximately 39,510 breast cancer–related deaths in the United States.1 Breast cancer has several known characteristics that determine aggressiveness and can be used as therapeutic targets as well as a means for monitoring responsiveness to therapy. These features are typically
Steroid Receptor Imaging
Approximately two-thirds of breast cancers are dependent on estrogen or progesterone or both for their growth.2 The stimulatory effect of estrogen and progesterone is mediated through nuclear estrogen receptors (ERs) and PgRs. To control the growth of hormone-dependent breast cancer, these receptors have been targeted by endocrine agents. The most widely used endocrine therapies include aromatase inhibitors (AIs) which deplete estrogen levels in vivo and within the tumor by disrupting estrogen
Conclusion
The modern era of targeted breast cancer treatment mandates assessment of tumor biology. Nuclear imaging tracers in development can help to determine molecular physiology in vivo. Novel tracers in breast cancer as we have reviewed herein have the potential to add meaningful biomarkers to clinical imaging and treatment trials, and portend an evolving clinical tool to study tumor molecular physiology with the potential to aid in diagnosis, treatment selection, drug development, and
References (72)
- et al.
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Ann Oncol
(2009) - et al.
In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET—Influence of menstrual cycle and endogenous estrogen level
Nucl Med Biol
(2007) - et al.
[18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERalpha-knockdown breast tumors in mice
Nucl Med Biol
(2012) - et al.
Specific progesterone receptors in human breast cancer
Steroids
(1975) - et al.
The pharmacology and clinical uses of tamoxifen
Pharmacol Ther
(1984) - et al.
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
Lab Invest
(2012) - et al.
Cancer statistics, 2012
CA Cancer J Clin
(2012) Hormone receptors: Their role in predicting prognosis and response to endocrine therapy
Semin Oncol
(1978)- et al.
A novel taspine derivative, HMQ1611, suppresses adhesion, migration and invasion of ZR-75-30 human breast cancer cells
Breast Cancer
(2012) - NCCN Guidelines....
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
J Clin Oncol
Acquisition of metastatic tissue from patients with bone metastases from breast cancer
Breast Cancer Res Treat
Designing steroid receptor-based radiotracers to image breast and prostate tumors
J Nucl Med
Breast cancer: PET imaging of estrogen receptors
Radiology
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol
J Nucl Med
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET
J Nucl Med
Uterine tumors: Pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET—Initial experience
Radiology
Additional value of 16alpha-[18F]fluoro-17beta-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET
Eur J Nucl Med Mol Imaging
PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma
J Nucl Med
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
Breast Cancer Res Treat
Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients
J Pharm Pharm Sci
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
J Clin Oncol
Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer
J Clin Oncol
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy
Clin Cancer Res
Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer
J Clin Oncol
Early results of an NCI-sponsored phase II study of 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer
J Nucl Med
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study
J Am Med Assoc
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
Eur J Nucl Med Mol Imaging Res
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer
Clin Cancer Res
Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen
Endocrinology
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
Breast Cancer Res Treat
The MPA mouse breast cancer model: Evidence for a role of progesterone receptors in breast cancer
Endocr Relat Cancer
Endocrine treatment of breast cancer in women
Endocr Rev
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
J Clin Oncol
Aromatase inhibitors: Rationale and use in breast cancer
Ann Rev Med
Cited by (47)
Advances in Breast PET Instrumentation
2024, PET ClinicsMolecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography
2022, Surgical Oncology Clinics of North AmericaBreast imaging
2022, Clinical PET/MRIA Role of PET Agents Beyond FDG in Gynecology
2019, Seminars in Nuclear MedicineReview of fluorescent steroidal ligands for the estrogen receptor 1995–2018
2019, SteroidsCitation Excerpt :Finally, recommendations will be provided concerning newer approaches for the development of “next-generation” fluorescently labeled estrogens. The rationale for developing fluorescent and other imaging agents for the estrogen receptor lies in its close association with hormone responsive diseases, particularly breast cancer [2]. According to the American Cancer Society, over 266,000 cases of breast cancer were predicted for 2018, and over 40,000 women dying from the disease [3].